Secretary of the State File Number
6375

Regulation of the

Department of Consumer Protection

Concerning

Drug Schedule Updates

Regulations adopted after July 1, 2013, become effective upon posting to the Connecticut eRegulations System, or at a later date if specified within the regulation.

Posted to the Connecticut eRegulations System on **February 10, 2023**

EFFECTIVE DATE
February 10, 2023

Approved by the Attorney General on
August 11, 2022

Approved by the Legislation Regulation Review Committee on
October 25, 2022

Electronic copy with agency head certification statement electronically submitted to and received by the Office of the Secretary of the State on
February 9, 2023

Form ICM-ECOPY (NEW 6/2015)
State of Connecticut
Secretary of the State

IMPORTANT NOTICE FOR CONNECTICUT STATE AGENCIES
This form should be used only for regulations first noticed *on and after March 23, 2015.*

Electronic Copy Certification Statement

(Submitted in accordance with the provisions of section 4-172 of the Connecticut General Statutes)

Regulation of the
Department of Consumer Protection
Concerning
Drug Schedule Updates

Approved by the Legislative Regulation Review Committee: **October 25, 2022**
eRegulations System Tracking Number: **PR2022-006**

I hereby certify that the electronic copy of the above-referenced regulation submitted herewith to the Secretary of the State is a true and accurate copy of the regulation approved in accordance with sections 4-169 and 4-170 of the *Connecticut General Statutes*.

And I further certify that in accordance with the approval of Legislative Regulation Review Committee, all required technical corrections, page substitutions and deletions, if any, have been incorporated into said regulation.

In testimony whereof, I have hereunto set my hand on **February 9, 2023**.

Julianne Avallone
Legal Director
Department of Consumer Protection

State of Connecticut
Regulation of
Department of Consumer Protection
Concerning
Drug Schedule Updates

Section 1. Sections 21a-243-7 to 21a-243-11, inclusive, of the Regulations of Connecticut State Agencies are amended to read as follows:

Sec. 21a-243-7. Controlled substances in schedule I

The controlled substances listed in this regulation are included by whatever official, common, usual, chemical, or trade name designation in [Schedule] schedule I:

(a) Any of the following opiates, including their isomers, esters, ethers, salts and salts of isomers, esters and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:
- (1) Acetylalpha-methylfentanyl;
- (2) Acetylmethadol;
- (3) Allylprodine;
- (4) Alphacetylmethadol (except Levo-alphacetylmethadol or LAAM);
- (5) Alphameprodine;
- (6) Alphamethadol;
- (7) Alpha-methylfentanyl;
- (8) Alphamethylthiofentanyl;
- (9) Benzethidine;
- (10) Betacetylmethadol;
- (11) Beta-hydroxy-fentanyl;
- (12) Beta-hydroxy-3-methylfentanyl;
- (13) Betameprodine;
- (14) Betamethadol;
- (15) Betaprodine;
- (16) Clonitazene;
- (17) Dextromoramide;
- (18) Diampromide;
- (19) Diethylthiambutene;
- (20) Difenoxin;
- (21) Dimenoxadol;
- (22) Dimepheptanol;
- (23) Dimethylthiambutene;
- (24) Dioxaphetyl Butyrate;
- (25) Dipipanone;
- (26) Ethylmethylthiambutene;
- (27) Etonitazene;
- (28) Etoxeridine;
- (29) Furethidine;

(30)Hydroxypethidine;
(31)Ketobemidone;
(32)Levomoramide;
(33)Levophenacylmorphan;
(34)3-methylfentanyl;
(35)3-methylthiofentanyl;
(36)Morpheridine;
(37)Noracymethadol;
(38)Norlevorphanol;
(39)Normethadone;
(40)Norpipanone;
(41)Para-fluorofentanyl;
(42)PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine);
(43)Phenadoxone;
(44)Phenampromide;
(45)Phenomorphan;
(46)Phenoperidine;
(47)Piritramide;
(48)Proheptazine;
(49)Properidine;
(50)Propiram;
(51)Racemoramide;
(52)Thiofentanyl;
(53)Tilidine;
(54)Trimeperidine.

(b) Any of the following opium derivatives, their salts, isomers and salts of isomers, unless specifically excepted whenever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:

(1) Acetorphine;
(2) Acetyldihydrocodeine;
(3) Benzylmorphine;
(4) Codeine methylbromide;
(5) Codeine-N-oxide;
(6) Cyprenorphine;
(7) Desomorphine;
(8) Dihydromorphine;
(9) Drotebanol;
(10)Etorphine, except hydrochloride salts;
(11)Heroin;
(12)Hydromorphinol;
(13)Methyldesorphine;
(14)Methyldihydromorphine;
(15)Morphine methylbromide;
(16)Morphine methylsulfonate;
(17)Morphine-N-oxide;
(18)Myrophine;

(19)Nicocodeine;
(20)Nicomorphine;
(21)Normorphine;
(22)Pholcodine;
(23)Thebacon.

(c) Any material, compound, mixture or preparation which contains their salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1) Alpha-ethyltryptamine;
(2) 4-bromo-2,5-dimethoxyamphetamine; or 4-bromo-2,5-DMA;
(3) 2,5-dimethoxyamphetamine; or 2,5-DMA;
(4) 2,5-Dimethoxy-4-ethylamphetamone or DOET;
(5) 3,4-M ethylenedioxy-N-ethylamphetamine;
(6) 1-methyl-4-phenyl-4-propionoxypiperidine; or MPPP;
(7) 3,4-methylenedioxymethamphetamine; or MDMA;
(8) 2,5-dimethoxy-4-(n)-propylthiopenenthylamine (2C-T-7);
(9) 4-methoxyamphetamine; or PMA;
(10)5-methoxy-3,4-methylenedioxy-amphetamine;
(11)5-Methoxy-nn-Diisopropyltryptamine(5-methoxy-dipt);
(12)4-methyl-2,5-dimethoxyamphetamine; or DOM; or STP
(13)3,4-methylenedioxy amphetamine; or MDA;
(14)N-hydroxy-3,4-methylenedioxyamphetamine (also known as N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA;
(15)3,4,5-trimethoxy amphetamine;
(16)benzylpiperazine or BZP;
(17)Bufotenine or Mappine;
(18)Alphaethyltryptamine;
(19)Diethyltryptamine or DET;
(20)Dimethyltryptamine or DMT;
(21)Ibogaine;
(22)Lysergic acid diethylamide;
(23)MDVP (3,4-methylenedioxypyrovalerone);
(24)3,4-methylenedioxy-N-methycathione (methylone)
(25)Mephedrone (4-methylmethcathinone);
(26)Mescaline;
(27)Parahexyl or Synhexyl;
(28)Peyote, meaning all parts of the plants;
(29)1-(2-phenylethyl)-4-phenyl-4-acetoxypiperidine; or PEPAP;
(30)N-ethyl-3-piperidyl benzilate;
(31)N-methyl-3-piperidyl benzilate;
(32)Psilocybin;
(33)Psilocyn;
(34)Tetrahydrocannabinols except Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States food and drug administration approved product;
(35)Salvia divinorum;

(36)Salvinorin A;
(37)Ethylamine analog of phencyclidine, Cyclohexamine or PCE;
(38)4-Bromo-2,5-dimethoxyphenethylamine;
(39)Pyrrolidine analog of phencyclidine, PCP or PHP;
(40)1-[1-(2-thienyl)cyclohexyl]pyrrolidine;
(41)Thiophene analog of phencyclidine, TPCP or TCP;
(42)Tiletamine or 2-(ethylamino)-2-(2-thienyl)-cyclohexanone;
(43)Trifluoromethylphenylpiperazine or TFMPP.

(d) Any material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, their salts, isomers and salts of isomers unless specifically excepted, wherever the existence of these salts, isomers and salts of isomers is possible within the specific chemical designation:
(1) Gamma-hydroxy butyric acid, except if contained in a drug product for which an application has been approved under section 505 of the [food, drug and cosmetic act] Food, Drug and Cosmetic Act;
(2) Gamma-butyrolactone;
(3) Mecloqualone;
(4) Methaqualone; or
(5) Zolazepam.

(e) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:
(1) Aminorex;
(2) N-benzylpiperazine (some other names: BZP; 1-benzylpiperazine);
(3) 4-Methylaminorex;
(4) Cathinone;
(5) Fenethylline;
(6) Methcathinone;
(7) N-ethylamphetamine;
(8) N,N-Dimethylamphetamine.

(f) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of a substance having a psychotropic response primarily by agonist activity at cannabinoid-specific receptors affecting the central nervous system. Specific compounds include, but are not limited to:
(1) 1-pentyl-3-(1-naphthoyl)indole (JWH-018);
(2) 1-butyl-3-(1-naphthoyl)indole (JWH-073);
(3) 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200);
(4) 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497);
(5) 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabi-cyclohexanol CP-47,497 C8 homologue).

(g) Any schedule I controlled substance, used for a medical purpose under the supervision of a practitioner, that has been approved by the federal Food and Drug Administration, or successor agency, to have a medical use and is reclassified in any schedule of the controlled substances or unscheduled under the federal Controlled Substances Act shall

have the same designation for state purposes as that designated under the federal Controlled Substances Act, unless otherwise specifically designated by the Commissioner of Consumer Protection in accordance with section 21a-243 of the Connecticut General Statutes.

Sec. 21a-243-8. Controlled substances in schedule II

The controlled substances listed in this regulation are included by whatever official, common, usual, chemical, or trade name designation in [Schedule] schedule II:

(a) Any of the following substances, except those narcotic drugs listed in other schedules, whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by combination of extraction and chemical synthesis:

(1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding Apomorphine, Dextrorphan, Nalbuphine, Naloxone, Nal-trexone, and their salts, but including the following: Raw opium, opium extracts, opium fluid extracts, powdered opium, granulated opium, tincture of opium, codeine, dihydroetorphine, ethylmorphine, etorphine hydrochloride, hydrocodone, hydromorhone, metopon, morphine, oripavine, oxycodone, oxymorphone and thebaine;

(2) [any] Any salt, compound,isomer, derivative or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (1), but not including the isoquinoline alkaloids of opium;

(3) [opium] Opium poppy and poppy straw;

(4) [coca] Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, but not including decocainized coca leaves or extractions which do not contain cocaine or ecgonine;

(5) [concentrate] Concentrate of poppy straw (the crude extract of poppy straw in either liquid, solid or powder form which contains the phenanthrine alkaloids of opium poppy).

(b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation, Dextrorphan and Levopropoxyphene excepted:

(1) Alfentanil;
(2) Alphaprodine;
(3) Anileridine;
(4) Bezitramide;
(5) [bulk] Bulk Dextropropoxyphene (nondosage forms);
(6) Carfentanil;
(7) Dihydrocodeine;
(8) Diphenoxylate;
(9) Fentanyl;
(10) Isomethadone;
(11) Levo-alphacetylmethadol or LAAM;
(12) Levomethorphan;
(13) Levorphanol;
(14) Metazocine;
(15) Methadone;

(16) Methadone-intermediate,4-cyano-2-dimethylamino-4,4-diphenylbutane;
(17) Moramide-Intermediate,2-methyl-3-morpholino-1,1-diphenyl-propane-carboxylic acid;
(18) Pethidine (Meperidine);
(19) Pethidine-Intermediate-A,4-cyano-1-methyl-4-phenylpiperidine;
(20) Pethidine-Intermediate-B,ethyl-4-phenylpiperidine-4-carboxylate;
(21) Pethidine-Intermediate-C, 1-methyl 4-phenylpiperidine-4-carboxylic acid;
(22) Phenazocine;
(23) Piminodine;
(24) Racemethorphan;
(25) Racemorphan;
(26) Remifentanil;
(27) Sufentanil;
(28) Tapentadol.

(c) Unless excepted or placed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system:

(1) Amphetamine, its salts, optical isomers, and salts of its optical isomers;
(2) [any] Any substance which contains any quantity of methamphetamine, including its salts, isomers, and salts of isomers;
(3) Methylphenidate;
(4) Phenmetrazine and its salts;
(5) Lisdexamfetamine and its salts, isomers and salts of isomers.

(d) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Amobarbital;
(2) Glutethimide;
(3) Pentobarbital;
(4) Phencyclidine; and
(5) Secobarbital.

(e) Hallucinogenic Substances:

(1) Nabilone.

(f) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances:

(1) Immediate precursor to Amphetamine and Methamphetamine; Phenylacetone (some trade names or other names); phenyl-2-propanone; P2P; benzyl methyl ketone; methyl benzyl ketone;
(2) [immediate] Immediate precursors to phencyclidine (PCP);
    (A) 1-phencylohexylamine;
    (B) 1-piperidinocyclohaxanecarbonitrile (PCC).

(g) Marijuana, (1) including any material, compound, mixture or preparation which contains its salts, isomers and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation, and (2) excepting any marijuana product that has been approved by the

federal Food and Drug Administration or successor agency to have a medical use and reclassified in any schedule of controlled substances or unscheduled by the federal Drug Enforcement Administration or successor agency. Any marijuana product described in subdivision (2) of this subsection shall be included in the same schedule designated by the federal Drug Enforcement Administration or successor agency.

(h) Any schedule II controlled substance, used for a medical purpose under the supervision of a practitioner, that has been approved by the federal Food and Drug Administration, or successor agency, to have a medical use and is reclassified in any schedule of the controlled substances or unscheduled under the federal Controlled Substances Act shall have the same designation for state purposes as that designated under the federal Controlled Substances Act, unless otherwise specifically designated by the Commissioner of Consumer Protection in accordance with section 21a-243 of the Connecticut General Statutes.

Sec. 21a-243-9. Controlled substances in schedule III

The controlled substances listed in this regulation are included by whatever official, common, usual, chemical, or trade name designation in [Schedule] schedule III:

(a) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
  (1) Benzphetamine;
  (2) Chlorphentermine;
  (3) Clortermine;
  (4) Phendimetrazine.

(b) Unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system:
  (1) Any compound, mixture or preparation containing: Amobarbital, Secobarbital, Pentobarbital or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule;
  (2) Any suppository dosage form containing Amobarbital, Secobarbital, Pentobarbital or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository;
  (3) Any substance which contains any quantity of a derivative of barbituric acid, or any salt of a derivative of barbituric acid, except those substances which are specifically listed in other schedules, except that the following analgesic products shall not be considered to be controlled substances:

(A) Products containing a ratio of fifteen milligrams of long or intermediate acting barbiturates combined with at least one of the following:
  (i) 188 mg aspirin;
  (ii) 375 mg salicylamide; or
  (iii) 70 mg phenacetin, acetanilid or acetaminophen;

(B) Products containing a ratio of fifteen milligrams of short acting barbiturates combined with at least one of the following:

(i) 307 mg aspirin;
(ii) 614 mg salicylamide; or
(iii) 106 mg phenacetin, acetanilid or acetaminophen;
(4) Any compound, mixture or preparation containing equal weights of both tiletamine and zolazepam or any salt thereof and not mixed with other psychoactive substances;
(5) Chlorhexadol;
(6) Embutramide;
(7) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a United States Food and Drug Administration approved drug product;
(8) Ketamine or any salt thereof;
(9) Lysergic acid;
(10) Lysergic acid amide;
(11) Methyprylon;
(12) Sulfondiethylmethane;
(13) Sulfonethylmethane;
(14) Sulfonmethane.

(c) Buprenorphine.

(d) Nalorphine.

(e) Any material, compound, mixture or preparation containing limited quantities of any of the following narcotic drugs or any salts thereof:
(1) Not more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium;
(2) [not] Not more than 1.8 grams of codeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
(3) [not] Not more than 300 milligrams of dihydrocodeinone, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium;
(4) [not] Not more than 300 milligrams of dihydrocodeinone, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
(5) [not] Not more than 1.8 grams of dihydrocodeine, or any of its salts, per 100 milliliters or not more than 90 milligrams per dosage unit,with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
(6) [not] Not more than 300 milligrams of ethylmorphine, or any of its salts, per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more ingredients in recognized therapeutic amounts;
(7) [not] Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
(8) [not] Not more than 50 milligrams of morphine, or any of its salts, per 100 milliliters or per 100 grams with one or more active, nonnarcotic ingredients in recognized therapeutic amounts.

(f) Unless expressly intended for administration through implants to nonhuman species and approved for such use by the [Federal] federal Food and Drug Administration, any anabolic

steroid including but not limited to, any of the following, or any isomer, ester, salt or derivative of the following that acts in the same manner on the human body:

(1) 3[beta],17-dihydroxy-5a-androstane;
(2) 3[alpha],17[beta]-dihydroxy-5a-androstane;
(3) 5[alpha]-androstan-3,17-dione;
(4) 1-androstenediol (3[beta],17[beta]-dihydroxy-5[alpha]-androst-1-ene);
(5) 1-androstenediol (3[alpha],17[beta]-dihydroxy-5[alpha]-androst-1-ene);
(6) 4-androstenediol (3[beta],17[beta]-dihydroxy-androst-4-ene);
(7) 5-androstenediol (3[beta],17[beta]-dihydroxy-androst-5-ene);
(8) 1-androstenedione ([5[alpha]]-androst-1-en-3,17-dione);
(9) 4-androstenedione (androst-4-en-3,17-dione);
(10) 5-androstenedione (androst-5-en-3,17-dione);
(11) Boldenone;
(12) Boldione;
(13) Chlorotestosterone;
(14) Clostebol;
(15) Dehydrochlormethyltestosterone;
(16) [Delta]1-dihydrotestosterone (a.k.a. '1-testosterone') (17[beta]- hydroxy-5[alpha]-androst-1-en-3-one);
(17) desoxymethltestosterone;
(18) Dihydrotesterone;
(19) Drostanolone;
(20) Ethylestrenol;
(21) Fluoxymesterone;
(22) Formebulone;
(23) Furazabol (17[alpha]-methyl-17[beta]-hydroxyandrostano[2,3-c]- furazan);
(24) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one;
(25) 4-hydroxytestosterone (4,17[beta]-dihydroxy-androst-4-en-3-one);
(26) 4-hydroxy-19-nortestosterone (4,17[beta]-dihydroxyestr-4-en-3- one);
(27) Mestanolone (17[alpha]-methyl-17[beta]-hydroxy-5-androstan-3- one);
(28) Mesterolone;
(29) Methandienone;
(30) Methandranone;
(31) Methandriol;
(32) Methandrostenolone;
(33) Methenolone;
(34) 17[alpha]-methyl-3[beta], 17[beta]-dihydroxy-5a-androstane;
(35) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy-5a-androstane;
(36) 17[alpha]-methyl-3[beta],17[beta]-dihydroxyandrost-4-ene;
(37) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one);
(38) Methyldienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one);
(39) Methyltrienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9-11-trien-3-one);

(40)Methyltesterone;
(41)Mibolerone;
(42)17[alpha]-methyl-[Delta]1-dihydrotestosterone (17b[beta]- hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one) (a.k.a. '17- [alpha]-methyl-1-testosterone');
(43)Nandrolone;
(44)19-nor-4,9 (10)-androstadienedione;
(45)19-nor-4-androstenediol (3[beta], 17[beta]-dihydroxyestr-4-ene);
(46)19-nor-4-androstenediol (3[alpha], 17[beta]-dihydroxyestr-4-ene);
(47)19-nor-5-androstenediol (3[beta], 17[beta]-dihydroxyestr-5-ene);
(48)19-nor-5-androstenediol (3[alpha], 17[beta]-dihydroxyestr-5-ene);
(49)19-nor-4-androstenedione (estr-4-en-3,17-dione);
(50)19-nor-5-androstenedione (estr-5-en-3,17-dione);
(51)Norbolethone (13[beta], 17[alpha]-diethyl-17[beta]-hydroxygon- 4-en-3-one);
(52)Norclostebol (4-chloro-17[beta]-hydroxyestr-4-en-3-one);
(53)Norethandrolone;
(54)Norethandrolone (17[alpha]-ethyl-17[beta]-hydroxyestr-4-en-3- one);
(55)Normethandrolone (17[alpha]-methyl-17[beta]-hydroxyestr-4-en-3-one);
(56)Oxandrolone;
(57)Oxymesterone;
(58)Oxymetholone;
(59)Stenbolone (17[beta]-hydroxy-2-methyl-[5[alpha]]-androst-1-en-3- one);
(60)Stanolone;
(61)Stanozolol;
(62)Testolactone;
(63)Testosterone;
(64)Tetrahydrogestrinone (13[beta], 17[alpha]-diethyl-17[beta]- hydroxygon-4,9,11-trien-3-one);
(65)Trenbolone.

(g) Chorionic gonadotropin[.], except when used for injection or implantation in cattle or any other nonhuman species and when such use is approved by the Food and Drug Administration or successor agency.

(h) Any quantity of the following substances having a depressant effect on the central nervous system, including their salts, isomers and salts of such isomers, and esters:
(1) Gamma-hydroxy butyric acid if contained in a product for which an application has been approved under section 505 of the federal food, drug and cosmetic act; or
(2) Gamma-butyrolactone.

(i) Any schedule III controlled substance, used for a medical purpose under the supervision of a practitioner, that has been approved by the federal Food and Drug Administration, or successor agency, to have a medical use and is reclassified in any schedule of the controlled substances or unscheduled under the federal Controlled Substances Act shall have the same designation for state purposes as that designated under the federal Controlled Substances Act, unless otherwise specifically designated by the Commissioner of Consumer Protection in accordance with section 21a-243 of the Connecticut General Statutes.

Sec. 21a-243-10. Controlled substances in schedule IV

The controlled substances listed in this regulation are included by whatever official, common, usual, chemical, or trade name designation in [Schedule] schedule IV:

(a) Any material, compound, mixture or preparation which contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system:
(1) Alprazolam;
(2) Barbital;
(3) Bromazepam;
(4) Camazepam;
(5) Carisoprodol;
(6) Chloral betaine;
(7) Chloral hydrate;
(8) Chlordiazepoxide;
(9) Clobazam;
(10) Clonazepam;
(11) Clorazepate;
(12) Clotiazepam;
(13) Cloxazolam;
(14) Delorazepam;
(15) Diazepam;
(16) Dochloralphenazone;
(17) Estazolam;
(18) Etholorvynol;
(19) Ethinamate;
(20) Ethyl-lofiazepate;
(21) Fludiazepam;
(22) Flunitrazepam;
(23) Flurazepam;
(24) Halazepam;
(25) Haloxazolam;
(26) Ketazolam;
(27) Loprazolam;
(28) Lorazepam;
(29) Lormetazepam;
(30) Mebutamate;
(31) Medazepam;
(32) Meprobamate;
(33) Methohexital;
(34) Methylphenobarbital (mephobarbital);
(35) Midazolam;
(36) Nimetazepam;
(37) Nitrazepam;
(38) Nordiazepam;
(39) Oxazepam;
(40) Oxazolam;

(41)Paraldehyde;
(42)Petrichloral;
(43)Phenobarbital;
(44)Pinazepam;
(45)Prazepam;
(46)Quazepam;
(47)Temazepam;
(48)Tetrazepam;
(49)Triazolam;
(50)Zaleplon;
(51)Zolpidem;
(52)Zopiclone.

(b) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1) Cathine;
(2) Diethylpropion;
(3) Fencamfamin;
(4) Fenproporex;
(5) Mazindol;
(6) Mefenorex;
(7) Modafinil;
(8) Pemoline
(9) Phentermine
(10)Pipradol;
(11)Sibutramine;
(12)SPA [(-)dimethylamino-1,2-diphenylethane].

(c) Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
(1) Fenfluramine.

(d) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or any salts thereof:
(1) Not more than 1 milligram of Difenoxin and not less than 25 micrograms of Atropine Sulfate per dosage unit;
(2) Dextropropoxyphene.

(e) Unless specifically exempted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including its salts:
(1) Butorphanol; or
(2) Pentazocine.

(f) Any schedule IV controlled substance, used for a medical purpose under the supervision of a practitioner, that has been approved by the federal Food and Drug Administration, or successor agency, to have a medical use and is reclassified in any schedule of the controlled substances or unscheduled under the federal Controlled Substances Act shall have the same designation for state purposes as that designated under the federal Controlled Substances Act, unless otherwise specifically designated by the Commissioner of Consumer Protection in accordance with section 21a-243 of the Connecticut General Statutes.

Sec. 21a-243-11. Controlled substances in schedule V

The controlled substances listed in this regulation are included by whatever official, common, usual, chemical, or trade name designation in [Schedule] schedule V:

(a) Any compound, mixture, or preparation containing limited quantities of any of the following controlled drugs, which also contain one or more noncontrolled active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation, valuable medicinal qualities other than those possessed by the controlled drug alone:

(1) [not] Not more than 200 milligrams of codeine, or any of its salts, per 100 milliliters or per 100 grams;

(2) [not] Not more than 100 milligrams of dihydrocodeine, or any of its salts, per 100 milliliters or per 100 grams;

(3) [not] Not more than 100 milligrams of ethylmorphine, or any of its salts, per 100 milliliters or per 100 grams;

(4) [not] Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit;

(5) [not] Not more than 100 milligrams of opium per 100 milliliters or per 100 grams;

(6) [not] Not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.

(b) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of such isomers:

(1) Pyrovalerone

(c) Any schedule V controlled substance, used for a medical purpose under the supervision of a practitioner, that has been approved by the federal Food and Drug Administration, or successor agency, to have a medical use and is reclassified in any schedule of the controlled substances or unscheduled under the federal Controlled Substances Act shall have the same designation for state purposes as that designated under the federal Controlled Substances Act, unless otherwise specifically designated by the Commissioner of Consumer Protection in accordance with section 21a-243 of the Connecticut General Statutes.

Statement of Purpose

This proposed regulation enables the Department of Consumer Protection to respond swiftly to changes made by the federal Food and Drug Administration and Drug Enforcement Agency regarding the designation of scheduled drugs. Drugs are consistently being added and removed from the controlled substances list and it is cumbersome to constantly revise regulations to reflect the state of Connecticut's agreement with the research and public safety assessment of the federal agencies overseeing the approval of such drugs. This regulation update will enable the swift state authorization of new drugs approved on a national scale.

Form Agency-Cert-PR-TA-ICM (Rev 11/2017)
State of Connecticut
Secretary of the State

IMPORTANT NOTICE FOR CONNECTICUT STATE AGENCIES
This form is to be used for proposed permanent and technical amendment regulations only and must be completed in full.

AGENCY CERTIFICATION

Department of Consumer Protection

Proposed Regulation Concerning

Drug Schedule Updates

eRegulations System Tracking Number **PR2022-006**

I hereby certify the following:

(1) The above-referenced **regulation** is proposed pursuant to the following statutory authority or authorities: **Conn. Gen. Stat. sections 21a-243 and 4-168**

For technical amendment regulations proposed without a comment period, complete #2 below, then skip to #8.

(2) As permitted by Section 4-168(h) of the *Connecticut General Statutes*, the agency elected to proceed without prior notice or hearing and posted the text of the proposed technical amendment regulation on eRegulations System website on **and N/A**.

For all other non-emergency proposed regulations, complete #3 - #7 below, then complete #8)

(3) The agency posted notice of intent with a specified comment period of not less than 30 days to the eRegulations System website on **June 30, 2022**.

(4) *(Complete one)* ☒ No public hearing held or was required to be held. **OR** ☐ One or more public hearings were held on: **N/A**.

(5) The agency posted notice of decision to move forward with the proposed regulation to the eRegulations System website on **August 3, 2022**.

(6) *(Complete one)* ☐ No comments were received. **OR** ☒ Comments were received and the agency posted the statements specified in subdivisions (1) and (2) of CGS Section 4-168(e) to the eRegulations System website on **August 3, 2022**.

(7) The final wording of the proposed regulation was posted to the eRegulations System website on **June 30, 2022**.

---

(8) Subsequent to approval for legal sufficiency by the Attorney General and approval by the Legislative Regulation Review Committee, **the final regulation shall be effective**

(Check one and complete as applicable)

☒ When posted to the eRegulations System website by the Secretary of the State.

OR ☐ On _____
(Date must be a specific calendar date not less than 11 days after submission to the Secretary of the State)

	Legal Director	8/3/2022
SIGNED *(Head of Board, Agency or Commission, or duly authorized deputy)*	OFFICIAL TITLE	DATE

OFFICE OF THE ATTORNEY GENERAL
REGULATION CERTIFICATION

Agency: Connecticut Department of Consumer Protection

***REGULATION NUMBER* PR2022-006**

This Regulation is hereby APPROVED by the Attorney General as to legal sufficiency in accordance with Connecticut General Statutes § 4-169.

DATE: 8/11/2022

Signed: /s/ Michael C. Wertheimer
Michael C. Wertheimer
Deputy Associate Attorney General/Chief of the Consumer Protection Section
Duly Authorized

The Connecticut General Assembly

Legislative Regulation Review Committee

Senator James Maroney
Senate Chair

Representative Nicole Klarides-Ditria
House Chair

Official Record of Committee Action

October 25, 2022

Agency:	Department of Consumer Protection
Description:	Drug Schedule Updates
LRRC Regulation Number:	2022-011
eRegulation Tracking Number:	PR2022-006

The above-referenced regulation has been

Approved with Technical Corrections

by the Legislative Regulation Review Committee in accordance with CGS Section 4-170.

Kirstin L. Breiner
Committee Administrator

State of Connecticut
Office of the Secretary of the State

Confirmation of Electronic Submission

Re: Regulation of the Department of Consumer Protection concerning Drug Schedule Updates
eRegulations System Tracking Number PR2022-006
Legislative Regulation Review Committee Docket Number 2022-011

The above-referenced regulation was electronically submitted to the Office of the Secretary of the State in accordance with Connecticut General Statutes Section 4-172 on February 9, 2023.

Said regulation is assigned Secretary of the State File Number 6375.

The effective date of this regulation is February 10, 2023.

Stephanie Thomas
Secretary of the State
February 10, 2023

By:

/s/ Christopher R. Drake
Christopher R. Drake
Director, Business Services Division